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The interrelation between the presence of circulating 
antigen-antibody complexes and the functional status of 
reticuloendothelial system Fc-receptors was studied in 
patients with systemic lupus erythematosus and Sjo-
gren's syndrome. Both groups of patients had a high 
prevalence of circulating immune complexes as detected 
by the 125I-Clq binding assay and the Raji cell radioim-
mune assay. A number of patients with both diseases 
were found to have abnormal reticuloendothelial system 
Fc-receptor function, as measured by the clearance of 
IgG-sensitized, 5 tCr-labeled autologous erythrocytes. In 
patients with systemic lupus erythematosus there was a 
high correlation between the presence and levels of im-
mune complexes and abnormal clearance rates. In Sjo-
gren's syndrome on the other hand there was no corre-
lation between the presence or levels of immune com-
plexes and clearance rates. In this disease patients with 
normal rates of clearance tended to have disease limited 
to exocrine glands, while patients with abnormal clear-
ance had evidence of more widespread tissue damage. 
These findings are consistent with the hypothesis that 
defective reticuloendothelial system function may lead 
to the prolonged circulation of immune complexes, 
thereby contributing to tissue damage. 
In the past few years there has been a tremendous increase 
in interest in the subject of circulating immune complexes and 
in the human diseases which may be mediated by them. This 
resurgence is in part due to the development of new, sensitive 
assays for detecting the presence of soluble antigen-antibody 
complexes in biologic fluids [1]. In addition there has been 
increasing interest in how circulating immune complexes are 
removed from the circulation. It has become increasingly ap-
parent that the reticuloendothelial system (RES) plays an 
important role in the clearance of soluble immune complexes. 
Over the past several years, the relationship between the pres-
ence of soluble immune complexes in serum and the functional 
capacity of the RES, as assessed by measurements of Fe IgG or 
C3b mediated clearance of immunologically active particles, 
has been the subject of intensive research at the National 
Institutes of Health. 
IMMUNE COMPLEX ASSAYS 
We have utilized 2 highly sensitive reproducible assays in the 
detection of circulating immune complexes, namely the 125I-Clq 
binding assay and the Raji cell radioimmune assay [2,3]. Clq is 
a subcomponent of the first component of complement (Cl). 
Clq will bind to immune complexes that contain IgG~, IgG2, 
IgG3 or IgM as well as to certain other polyanionic substances 
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such as bacterial endotoxin or DNA. The binding of Clq to 
immune complexes takes place via noncovalent bonding to the 
immunoglobulin molecule. The Clq molecule can be purified 
from human serum and utilized for the detection and quanti-
tation of immune complexes in biologic fluids. The 125I-Clq 
binding assay is performed by mixing the test serum with 
EDT A which dissociates the native Cl molecule into its sub-
components Clq, Clr and Cis. This dissociation is thought to 
enhance the exchange of the exogenous 125I-Clq added with the 
native Clq, r, s complex which may be bound to the complexes 
in the serum sample. The EDT A-serum mixture is. then allowed 
to react with the 125I-Clq. Free Clq is separated from Clq bound 
to immune complexes by precipitation of the Clq in the complex 
aggregate with polyethylene glycol (PEG), and the amount of 
radioactivity precipitated is quantitated. Results can then be 
expressed as percent 125Clq precipitated. This test is quite 
sensitive, highly reproducible and does not give false positive 
results in sera containing bacterial endotoxin or DNA because 
these substances are relatively soluble in·the low strength-PEG 
solution used in this assay [ 4]. 
The second immune complex assay which we utilize is the 
Raji cell radioimmune assay. Raji cells are a cultured lympho-
blastoid cell line with B-cell characteristics originally derived 
from a patient with Burkitt's lymphoma [5]. These cells lack 
membrane bound immunoglobulin, but possess receptors for 
the Fe portion of human IgG as well as for Clq, C3b, and C3d. 
The immune complex assay is based on the ability of Raji cells 
to bind immune complexes which have activated complement. 
The majority of this binding is through the cell swface comple-
ment receptors, presumably because the complement receptors 
are either present in greater number than Fe receptors or have 
a higher affinity for their ligands. The assay is performed by 
incubating an appropriate dilution of the test serum with a 
fixed number of viable Raji cells. After washing the cells thor-
oughly, 1251 rabbit anti human IgG is added to the cells. The 
amount of uptake of radioactivity is used as a measure of the 
amount of immune complexes present in the test serum. 
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RETICULOENDOTHELIAL SYSTEM CLEARANCE 
The RES has been known to play an important role in the 
cleru·ance of foreign materials from the circulation for many 
years. Techniques for studying the functional capacity of the 
RES in man have in the past utilized pru·ticulate materials such 
as radiolabeled aggregated human serum albumin or colloidal 
lipids [6]. It was thought that the RES phagocytic index derived 
from these studies was a valid measure of overall RES function. 
However, when a vru·iety of inflammatory diseases were studied, 
t hey were characterized by accelerated rather than delayed 
cleru·ance of the pru·ticles from the bloodstream, and thus de-
fective RES function was not found to be a distinctive feature 
of any illness studied including systemic lupus erythematosus. 
More recently the existence of specific cell smface receptors 
on the macro phages of the RES has been demonstrated. These 
phagocytic cells have cell surface receptors for the Fe portion 
of IgG and a cleavage product of the third component of 
complement C3b. These receptors have been shown, particu-
lru·ly through studies of autoimmune hemolytic anemia [7], to 
function in the attachment and the ingestion of pru·ticles coated 
with these substances. Functional studies of the ability of the 
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RES to clear immunologically active particles from the circu-
lation have recently become possible, through the work of 
Frank and co-workers. Briefly, one can radiolabel washed au-
tologous RBC's with 51Cr, and coat their surface with either 
highly purified, non complement fixing anti-Rh(D) IgG mole-
cules or with complement fixing IgM isoagglutinin or cold 
agglutinin antibodies. These autologous RBC's are then rein-
jected intravenously and their rate of disappearance over time 
is measured. The resultant curve is a measure of clearance as 
mediated either by Fe IgG receptors or C3b receptors. 
In the studies described below both of these areas of study 
are discussed i.e., immune complex assays and measurement of 
RES Fe IgG mediated clearance. We sought to examine the 
relationships between these parameters, clinical disease activity 
and other measurements of disease activity in patients with 
systemic lupus erythematosus and in patients with Sjogren's 
syndrome. 
STUDIES OF SYSTEMIC LUPUS ERYTHEMATOSUS 
(SLE) : 
Systemic lupus erythematosus is considered by many to be 
the prototype immune complex disease in man [9]. Antigen-
antibody complexes are present in patients with active disease 
and are thought to be important pathogenetically through 
activation of the complement system and other mediators of 
int1ammation as well as through deposition of the immune 
complexes in various organs causing tissue damage. We exam-
ined the sera of 15 newly diagnosed patients with SLE, who 
had never been treated with corticosteroids or cytotoxic agents, 
for the presence of circulating immune complexes using the 1251-
Clq binding assay and the Raji cell radioimmune assay [10]. 
We found that 13 of 15 patients (86%) had increased Clq binding 
activity (BA) (>10%) and that 9 of these 13 had marked 
increases (35-85%) in Clq BA (Fig 1). Of the 14 patients tested 
in the Raji cell radioimmune assay, immune complexes were 
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FIG 1. Results of t he '""I-Clq binding assay in normal subjects and 
15 patients with systemic lupus erythematosus. Upper limit of normal 
is 10%. 
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FIG 2. Immune complex levels and disease activity in systemic lupus 
erythematosus (From reference 10, reprinted with permission of New 
England Journal of Medicine). 
found in 13 of 14 (93%). The concordance between the assays 
was 79%. When the Clq BA of these sera were compared with 
an independently assessed score of disease activity (0-3+ ), it 
was found that the 2 were highly correlated (rho = 0.834, p < 
0.001) (Fig 2). That is, patients with the highest levels of Clq 
BA had the most severe disease activity while patients who had 
low levels of circulating immune complexes had less severe 
disease. Comparison of the results of the Raji cell radioimmune 
assay with the disease activity score showed that these 2 
parameters were also highly correlated (rho= 0.673, p < 0.005). 
The RES Fe receptor mediated clearance of the 51Cr-labeled 
lgG-sensitized autologous erythrocytes was measured simulta-
neously in these 15 patients. Thirteen of 15 had moderate to 
marked defects in clearance (Fig 3) . The T V2 (the time in which 
50% of the cells are removed from the circulation) in these 
patients ranged from 80 to 2256 min as compared to an upper 
95% confidence limit of 62 minutes in 13 normal controls. Thus 
Fe-receptor function was depressed in most patients. When the 
T V2 of each patient was compared with the disease activity 
score, it was found that they were significantly correlated (rho 
= 0.791, p < 0.001). Patients with the most clinically severe 
disease had the most prolonged clearance while those with 
milder disease had clearance rates closer to normal. 
The magnitude of the clearance defect and the level of 
circulating immune complexes as measured by the serum Clq 
BA were significantly correlated (p < 0.025) (Fig 4). The results 
of the. Raji cell assay were also highly correlated with the 
decreased RES clearance rates in these patients. Serum levels 
of C3, C4, and CH50 were depressed in most patients, and anti-
DNA antibodies were present in 13 patients. Serum comple-
ment levels and anti-DNA antibody titers were also correlated 
with the levels of circulating immune complexes but not with 
the clearance times . 
This study demonstrated that profound defects in RES Fc-
receptor function exist in most patients with active SLE. These 
patients might also have difficulty in clearing soluble immune 
complexes from the circulation. Indeed most of these patients 
do have circulating immune complexes. The significant corre-
lation between Clq BA and the clearance defect suggests that 
defective RES function contributes to the prolonged circulation 
of immune complexes in patients with SLE. 
The reason for the defective RES function in these patients 
is not clear. It may be on the basis of saturation of Fe-receptors 
by immune complexes, with resultant competitive inhibition 
causing further accumulation of complexes in the cil·culation. A 
somewhat less likely possibility is that there is a primary defect 
in Fc-receptor function in patients with SLE, which makes it 
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Ftc 3. Reticuloendothelial system Fc-specific clearance (T'/, = half-
life) in normal subjects and patients with systemic lupus erythematosus 
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Ftc 4. Immune complex levels and Fc-specific clearance in systemic 
lupus erythematosus (Clq BA = Clq Binding Activity). *Positive by 
Raji cell assay (From reference 10, reprinted with permission of New 
England Journal of M edicine). 
difficul t for patients to clear immune complexes from the cir-
culation efficiently. 
STUDIES OF SJOGREN'S SYNDROME 
Sjogren's syndrome (SS) is a cluonic autoimmune disease of 
unknown etiology that has a broad clinical and histopathologi-
cal spectrum [11]. Patients with SS have a high incidence of 
nonorgan specific autoantibodies such as rheumatoid factor and 
are known to develop vasculitis, myositis, neuritis and glomer-
ulonephritis [11- 13). We studied 55 patients with SS to deter-
mine whether immune complexes existed in these patients, to 
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assess their relationship to clinical disease, to examine the 
physico-chemical characteristics of th e complexes and to 
measm e the functional capacity of the RES Fc-IgG receptors 
in these patients (14,15). 
Increased 125I-Clq BA (>10%) was found in the sera of 47 of 
55 (85%) patients. The range of Clq BA was from 2% to 98% 
with a m ean of 48% (Fig 5). IgM RF was present in t he sera of 
35 (64%) patients. A positive association was found between the 
Clq BA and the titer of IgM RF, despite the finding t hat 14 
patients had increased Clq BA and no RF and 2 patients had 
normal Clq BA in t he presence of RF. 
The Raji cell assay was positive (>20 llg equivalents HGG/ 
ml) in 17 of 20 (85%) SS patients tested. The range was from 0 
to 760 1-Lg/ ml . with a mean of 163 1-Lg/ ml. IgM RF was present in 
15 of 20 sera, but th ere was no correlation between resul ts of 
t he Raji cell and th e amount of IgM RF . 
The sera of 20 SS patients were tested by both immune 
complex assays and both were positive in 17 of 20 sera. There 
was concordance of the two assays in 18 (90%) sera. 
The total group of SS patients could be broken down into 4 
clinical subgroups: 19 patien ts had SS limited to exocrine 
glands, 17 patients had SS with involvement of extraglandular 
tissues, 11 patients had SS plus RA, 8 patients had SS plus 
another connective t issue disease. When the results of th e Clq 
binding assay and Raji cell assay were analyzed, there were no 
significan t differences between the clinical subgroups with re-
gard to the prevalence or amount of immune complexes de-
tected . 
In order to more closely examine the relationship between 
IgM RF and the Clq BA in the sera of SS patients, th e effect of 
t reatment of sera with 2-mercaptoethanol (2-ME) was studied. 
2-ME is a strong disulfide reducing agent capable of dissociating 
pentameric IgM into its subunits and thus destroyin g IgM RF 
activity. Clq BA and RF were measm ed in the sera of 17 
patients with ss before and after treatment with 10- 2 M 2-ME 
(Fig 6). RF, which ranged in titer from 64 to 8,192, was elimi-
nated in all 13 patients in whom it was present. In contrast the 
effect of 2-ME on Clq BA varied from minimal to moderate 
(mean decrement = 9%). This suggested that th e Clq binding 
material in t he sera of patients with SS was distinct from 198 
IgM RF. 
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undertaken using a substance called protein A. Protein A is a 
staphylococcal cell surface protein with a marked affinity for 
l gG (subclasses 1, 2, and 4). The effect of absorption of SS sera 
with solid phase protein A was studied in 6 patients. All sera 
ini t ially had high Clq BA (26-81 %) and RF titers from 0 to 
4096. Protein A absorption caused decreases in Clq BA to 
normal levels in ali cases. The effect ofRF activity was variable. 
This suggested that IgG antibody is a constituent of the Clq 
binding material. In addition the absorbed material could be 
eluted from the solid phase protein A, added to normal human 
serum, and shown to induce abnormal Clq BA, suggesting that 
t his may be a valuable method of partially purifying immune 
complexes. 
Since this study clearly demonstrated that a high percentage 
of SS patients have immune complex-like material in their 
serum, it was of interest to evaluate the functional status of 
RES Fc-IgG receptors in these patients. Nineteen patients were 
studied. Six patients had SS limited to exocrine glands, 7 
patients had involvement of extraglandular tissues, and 6 pa-
tients had SS plus another connective tissue disease. Twelve of 
t he 19 patients had delayed clearance of the IgG sensitized 
erythrocytes. The T Ws ranged from 80 to 356 min while the 
upper limit of normal was 62 min. There was a clear association 
between the clinical subgroup and the existence of a clearance 
defect. Eleven of the 12 patients with delayed Fe mediated 
clearance had SS plus extraglandular manifestations or SS plus 
another connective tissue disease. Only one patient with abnor-
mal clearance had SS alone. 
Five of the 7 patients with normal Fe receptor function had 
SS alone without extraglandular disease. The 2 other patients 
had pseudolymphoma with hepatosplenomegaly. Animal stud-
ies have demonstrated that Fe receptor mediated clearance of 
immunologically active particles is greatly augmented in the 
presence of splenomegaly [16]. Thus it was interesting that the 
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only 2 patients with widespread disease and normal clearance 
were the 2 in the group of 19 patients who had enlarged spleens. 
The association of normal clearance with SS alone and pro-
longed clearance with SS and extraglandular manifestations or 
a connective t issue disease was statistically significant (p < 
0.025). 
Elevated 12r'I-Clq BA was found in the serum of 15 of 19 
patients with SS. Ten of the 12 patients with abnormal RES 
clearance had elevated Clq BA (17-79%) but 5 of 7 patients 
with normal Fe mediated clearance also had high Clq BA (30-
79%). There was no association between delayed clearance rates 
and the presence or level of elevated Clq BA. 
Thus we have presented evidence that patients with 2 dis-
eases i.e. , SLE and Sjogren's syndrome, have circulating im-
mune complexes and a defect in Fe mediated RES clearance. 
In SLE, there is a high correlation between the presence and 
amount of immune complexes and activity of disease and be-
tween the presence and amount of immune complexes and the 
existence and severity of the RES clearance defect. In SS 
however there is no correlation between the presence and 
amount of immune complexes and the clinical type of disease 
nor between the presence and amount of immune complexes 
and the severity of the RES clearance defect. In SLE, it has 
been postulated that circulating immune complexes might sat-
urate Fe receptor sites and competitively inhibit the binding of 
the IgG coated autologous eryt hrocytes. However, this could 
not be the case in SS unless the types of immune complexes in 
patients with SS with widespread disease had different prop-
erties than those with more localized disease since both groups 
have the same levels of immune complexes. Alternatively the 
existence of a primary defect in RES Fe receptor function is 
possible in patients with SLE but seems less likely in patients 
with SS. Patients with localized disease who might potentially 
develop more widespread illness appear not to have a clearance 
defect when they have only localized disease. 
It is hoped that further study of the relationship between 
circulating immune complexes and reticuloendothelial system 
function as well as further characterization of the immune 
complexes will increase our understanding of the role of circu-
lating antigen-antibody complexes in the pathogenesis of a 
variety of diseases. 
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DISCUSSION 
DR. GREEN: Why do you think that there is a ·correlation between 
Fe IgG clearance rates and immune complex levels in patients with 
systemic lupus erythematosus while there is no correlation between 
clearance and immune complex levels in patients with Sjogren's syn-
drome? 
DR. LAWLEY: The reasons for the different findings in these 2 
diseases are not clear. The findings in systemic lupus of erythematosus 
are consistent with the hypothesis that circulat ing immune complexes 
can saturate the Fe receptors resulting in prolonged clearance rates. 
For this same hypothesis to apply in patients with Sjogren's syndrome 
one would have to postulate the existence of multiple types of immune 
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complexes with different biologic properties in these patients. The 
assays which are used to detect circulating immune complexes may not 
be able to distinguish different kinds of immune complexes, and it may 
be that Sjogren's patients with widespread disease have a type of 
complex that can block Fe receptors and eventually be deposited in 
tissue while those with localized disease do not. Alterna tively it is 
possible that patients with localized disease who progress to more 
widespread illness might at that time have a change in the functional 
status of their Fe receptors either primarily or due to unknown circu-
lating factors that would influence clearance rates. 
DR. GIGLI: Have C3b clearance studies been performed on these 
patients? 
DR. LAWLEY: These studies are currently underway, but too few 
patients have been studied to draw a ny meaningful conclusions. 
DR. PROVOST: Were serum complement levels measuYed in the 
patients with Sjogren's syndrome and was there any correlation with 
levels of immune complexes or clearance rates? 
DR. LAWLEY: We measured serum functional C4 levels and serum 
antigenic C3 levels in these patients. In general the complement levels 
were normal and not correlated with either clearance rates or immune 
complex levels. We did not attempt to assay for the presence of split 
products. 
DR. SHEVACH: What serological parameters correlated best with the 
disease activity score in the patients with systemic lupus erythemato-
sus? 
DR. LAWLEY: Serum antigenic C3 levels, and anti DNA antibody 
titers were both significantly correlated with disease activity in this 
group of patients. However, the Clq binding assay proved to be the 
most useful test of disease activity, giving a correlation coefficient (rho) 
of 0.834. 
